+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
BCMA-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032- Product Image
BCMA-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032- Product Image
Sale

BCMA-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6078933
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The BCMA-targeted CAR-T Cell Therapy Market is projected to reach USD 4.27 Billion in 2026. It is expected to continue growing at a CAGR of 23.59%, reaching USD 15.35 Billion by 2032.

BCMA-Targeted CAR-T Cell Therapy: Executive Overview

BCMA-targeted CAR-T cell therapy is an adoptive immunotherapy designed to recognize B-cell maturation antigen on malignant plasma cells. Its principal clinical relevance is in relapsed or refractory multiple myeloma, where treatment involves patient-cell collection, genetic modification, manufacturing, lymphodepletion, and reinfusion. The field is shaped by response durability, manufacturing reliability, safety management, treatment access, and the development of earlier-line applications.

Clinical and Operational Shifts Reshaping BCMA CAR-T Therapy

The landscape is moving from proof of concept toward integration into complex myeloma treatment pathways. Key shifts include evaluation in earlier lines of therapy, efforts to improve persistence and reduce relapse, streamlined manufacturing and logistics, and stronger requirements for managing cytokine release syndrome, neurotoxicity, prolonged cytopenias, infections, and delayed immune recovery. Real-world implementation is also increasing attention on referral networks, cellular-therapy infrastructure, caregiver support, and long-term follow-up.

Artificial Intelligence Across Discovery, Manufacturing, and Care

Artificial intelligence can support BCMA-targeted CAR-T development by identifying biological response patterns, prioritizing construct designs, and integrating genomic, transcriptomic, and clinical data. In manufacturing, analytical models may help detect process deviations, optimize release testing, and improve scheduling. In clinical practice, AI-assisted risk stratification could support monitoring for toxicity and relapse, but its use requires representative datasets, transparent validation, cybersecurity controls, and clinician oversight. AI should augment-not replace-clinical judgment and regulatory accountability.

Regional Insights Across the Global Treatment Landscape

North America has advanced cellular-therapy infrastructure and specialized treatment centers, while Europe emphasizes coordinated regulation, evidence generation, and equitable access across health systems. Asia-Pacific combines strong biomedical capability with substantial variation in reimbursement, manufacturing capacity, and regulatory pathways. Latin America is developing referral and cell-therapy capabilities but faces logistical and affordability constraints. The Middle East is investing selectively in advanced oncology services, and Africa remains focused on building diagnostic, referral, transplantation, and supportive-care foundations needed for broader access.

How ASEAN, BRICS, EU, G7, GCC, and NATO Align With Sector Priorities

ASEAN’s relevance lies in improving cross-border referral, regulatory coordination, and specialist capacity across diverse health systems. BRICS countries present varied strengths in clinical research, manufacturing, and public-sector oncology delivery, alongside uneven access. The European Union benefits from regional scientific collaboration but must address differences in reimbursement and center readiness. G7 members generally have mature research and cellular-therapy ecosystems, while GCC states are expanding advanced-care infrastructure through centralized investment. NATO is not a health-market bloc, but several NATO members contribute to research, regulation, clinical delivery, and resilient supply-chain planning.

Country-Level Conditions Shaping Adoption and Access

The United States and Canada have established cellular-therapy networks and specialist expertise. The United Kingdom, France, Germany, Italy, and Spain combine advanced hematology services with health-technology assessment and reimbursement considerations that influence access. Australia and Japan have developed sophisticated oncology and cell-therapy capabilities, while South Korea is strengthening biotechnology and clinical infrastructure. China is expanding domestic research, manufacturing, and treatment capacity. India is building capability amid pronounced affordability and access challenges. Brazil and Mexico are developing referral, regulatory, and treatment networks. Russia has scientific and clinical capacity but faces constraints related to international collaboration, procurement, and technology access.

Actions for Leaders to Strengthen BCMA CAR-T Delivery

Industry leaders should prioritize clinically meaningful differentiation, durable outcomes, and transparent safety evidence rather than relying only on initial response rates. They should invest in robust manufacturing controls, decentralized or regional capacity where appropriate, and logistics systems that protect product quality. Partnerships with treatment centers can improve referral pathways, caregiver education, toxicity management, and follow-up. Access strategies should address reimbursement, patient selection, workforce training, and treatment disparities. Leaders should also establish responsible AI governance, including validation, auditability, privacy protection, and continuous monitoring for bias.

Research Methodology for the Executive Summary

This summary applies a structured qualitative synthesis of the supplied market scope-BCMA-targeted CAR-T cell therapy-across clinical development, manufacturing, regulation, delivery infrastructure, access, and technology. Insights are organized by required regions, country groupings, and countries, with emphasis on documented industry dynamics rather than numerical market claims. The assessment distinguishes established therapy characteristics from emerging opportunities and avoids unsupported estimates, forecasts, market shares, and company-specific assertions. Regional comparisons reflect differences in healthcare capacity, regulation, reimbursement, research intensity, and logistics.

Conclusion: Building a More Durable and Accessible Treatment Ecosystem

BCMA-targeted CAR-T cell therapy is progressing within a demanding environment that links cellular engineering, hematologic oncology, manufacturing, and specialized care. Sustainable advancement will depend on improving durability and safety while making treatment pathways more reliable and accessible. Regional capability, national policy, coordinated referral systems, and responsible use of artificial intelligence will collectively determine how effectively the therapy reaches appropriate patients and delivers lasting clinical value.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. BCMA-targeted CAR-T Cell Therapy Market, by Product Type
7.1. Introduction
7.2. Allogeneic
7.3. Autologous
8. BCMA-targeted CAR-T Cell Therapy Market, by Line Of Therapy
8.1. Introduction
8.2. Fourth Line And Beyond
8.3. Second Line
8.4. Third Line
9. BCMA-targeted CAR-T Cell Therapy Market, by Manufacturing Type
9.1. Introduction
9.2. Contract Manufacturing
9.3. In-House Manufacturing
10. BCMA-targeted CAR-T Cell Therapy Market, by End User
10.1. Introduction
10.2. Hospitals
10.2.1. Academic Hospitals
10.2.2. Community Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
10.4.1. Oncology Centers
10.4.2. Outpatient Clinics
11. BCMA-targeted CAR-T Cell Therapy Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. BCMA-targeted CAR-T Cell Therapy Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. BCMA-targeted CAR-T Cell Therapy Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Arcellx Inc.
15.2. Autolus Therapeutics plc
15.3. bluebird bio Inc.
15.4. Bristol Myers Squibb Company
15.5. CARsgen Therapeutics Holdings Limited
15.6. Cartesian Therapeutics
15.7. Cellular Biomedicine Group Inc.
15.8. Gilead Sciences Inc.
15.9. Gracell Biotechnologies Ltd.
15.10. Janssen Biotech Inc.
15.11. JW Therapeutics Co. Ltd.
15.12. Kite Pharma Inc.
15.13. Legend Biotech Corporation
15.14. Novartis AG
15.15. Poseida Therapeutics Inc.
15.16. Shanghai Unicar-Therapy Bio-medicine Technology Co. Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global BCMA-targeted CAR-T Cell Therapy Market, Years Considered for the Study
FIGURE 2. Global BCMA-targeted CAR-T Cell Therapy Market, Research Design
FIGURE 3. Global BCMA-targeted CAR-T Cell Therapy Market, Research Framework
FIGURE 4. Global BCMA-targeted CAR-T Cell Therapy Market, Data Triangulation
FIGURE 5. Global BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 9. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2025 vs 2032 (%)
FIGURE 11. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global BCMA-targeted CAR-T Cell Therapy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global BCMA-targeted CAR-T Cell Therapy Market Segmentation & Coverage
TABLE 2. Global BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 11. Global Fourth Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Fourth Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Fourth Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 21. Global Contract Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Contract Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Contract Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global In-House Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global In-House Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global In-House Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 28. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Academic Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Academic Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Academic Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Community Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Community Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Community Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Oncology Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Oncology Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Oncology Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Outpatient Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Outpatient Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Outpatient Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 57. North America BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. North America BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 59. North America BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 60. North America BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 61. North America BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 62. North America BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 63. North America BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 64. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 66. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 67. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 68. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 69. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 70. Latin America BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 71. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 73. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 74. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 75. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 76. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 77. Europe BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 78. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 81. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 82. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 84. Middle East BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 85. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 88. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 89. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 91. Africa BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 92. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 96. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 97. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 99. ASEAN BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 100. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 102. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 103. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 104. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 106. GCC BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 107. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 109. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 110. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 111. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 113. European Union BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 114. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 117. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 118. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 120. BRICS BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 121. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 124. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 125. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 127. G7 BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 128. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 131. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 132. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 134. NATO BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 135. Global BCMA-targeted CAR-T Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. United States BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 137. United States BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. United States BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 139. United States BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 140. United States BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. United States BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 142. United States BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 143. Canada BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 144. Canada BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 145. Canada BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 146. Canada BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 147. Canada BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Canada BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 149. Canada BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 150. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 151. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 153. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 154. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 156. Mexico BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 157. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 158. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 160. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 161. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 163. Brazil BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 164. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 165. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 166. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 167. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 168. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 170. United Kingdom BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 171. Germany BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 172. Germany BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Germany BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 174. Germany BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 175. Germany BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Germany BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 177. Germany BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 178. France BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 179. France BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. France BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 181. France BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 182. France BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. France BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 184. France BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 185. Russia BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 186. Russia BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. Russia BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 188. Russia BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 189. Russia BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Russia BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 191. Russia BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 192. Italy BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 193. Italy BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 194. Italy BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 195. Italy BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 196. Italy BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Italy BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 198. Italy BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 199. Spain BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 200. Spain BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. Spain BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 202. Spain BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 203. Spain BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. Spain BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 205. Spain BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 206. China BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 207. China BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. China BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 209. China BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 210. China BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. China BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 212. China BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 213. India BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 214. India BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 215. India BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 216. India BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 217. India BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. India BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 219. India BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 220. Japan BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 221. Japan BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 222. Japan BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 223. Japan BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 224. Japan BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Japan BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 226. Japan BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 227. Australia BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 228. Australia BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. Australia BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 230. Australia BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 231. Australia BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Australia BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 233. Australia BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 234. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 235. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 237. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, by Manufacturing Type, 2017-2032 (USD Million)
TABLE 238. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 240. South Korea BCMA-targeted CAR-T Cell Therapy Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 241. Global BCMA-targeted CAR-T Cell Therapy Market Share, by Key Player, 2025
TABLE 242. Global BCMA-targeted CAR-T Cell Therapy Market, Key Experts

Companies Mentioned

  • Arcellx Inc.
  • Autolus Therapeutics plc
  • bluebird bio Inc.
  • Bristol Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited
  • Cartesian Therapeutics
  • Cellular Biomedicine Group Inc.
  • Gilead Sciences Inc.
  • Gracell Biotechnologies Ltd.
  • Janssen Biotech Inc.
  • JW Therapeutics Co. Ltd.
  • Kite Pharma Inc.
  • Legend Biotech Corporation
  • Novartis AG
  • Poseida Therapeutics Inc.
  • Shanghai Unicar-Therapy Bio-medicine Technology Co. Ltd.

Related Topics

Related Reports

CAR T-Cell Therapy for Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

CAR T-Cell Therapy for Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region, 2025-2035 - Product Image

CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region, 2025-2035

  • Report
  • Global
From
CAR T - Cell Therapy - Competitive Landscape, 2026 - Product Image

CAR T - Cell Therapy - Competitive Landscape, 2026

  • Report
  • 500 Pages
  • Global
From
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - Product Image

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

  • Report
  • 598 Pages
  • Global
From
CAR T-cell Therapy Market - Global Forecast 2026-2032 - Product Image

CAR T-cell Therapy Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.